CAM
VNDA icon

Cresset Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Cresset Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,227
Closed -$161K – 1152
2021
Q4 		$161K Buy
+10,227
New +$178K ﹤0.01% 1068
2019
Q2 		– Sell
-60
Closed -$1K – 1674
2019
Q1 		$1K Sell
60
-48
-44% -$1.09K ﹤0.01% 1886
2018
Q4 		$3K Buy
+108
New +$2.54K ﹤0.01% 1226

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Cresset Asset Management's VNDA Position: Q1 2022 in Review

Cresset Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2022, closing a stake of 10,227 shares — an estimated $161K sold.

Cresset Asset Management first reported a position in VNDA in Q4 2018 and held it in 3 quarters. The position peaked at $161K in Q4 2021. 188 funds tracked by Wall St. Rank hold VNDA as of Q1 2022.

  • Cresset Asset Management reported no remaining Vanda Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Cresset Asset Management sold 10,227 Vanda Pharmaceuticals shares in Q1 2022, an estimated $161K.
  • Cresset Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Cresset Asset Management's Vanda Pharmaceuticals position peaked at $161K in Q4 2021.
  • 188 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2022.

Based on Cresset Asset Management's 13F filing for Q1 2022, filed 16 May 2022.